C-reactive protein levels and survival in patients with moderate to very severe COPD

Chest

Volumn 133, Issue 6, 2008, Pages 1336-1343

  De Torres, Juan P ^a   Pinto Plata, Victor ^b   Casanova, Ciro ^a   Mullerova, Hanna ^c   Córdoba Lanús, Elizabeth ^a   Muros De Fuentes, Mercedes ^a   Aguirre Jaime, Armando ^a   Celli, Bartolome R ^b  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b ST ELIZABETH'S MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

C reactive protein; COPD; Survival

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTERIAL OXYGEN SATURATION; ARTICLE; BODY MASS; CHARLSON COMORBIDITY SCORE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DISEASE SEVERITY; DYSPNEA; EPIDEMIOLOGICAL DATA; EVALUATION; EXERCISE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH COUNCIL SCALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; SCORING SYSTEM; SURVIVAL; TOTAL LUNG CAPACITY; WALKING;

EID: 45949086220     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-2433     Document Type: Article

References (29)

1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364:613-620
2. Pauwels R, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276
3. Agustí A. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2:367-370
4. Gan WQ, Man SFP, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and meta-analysis. Thorax 2004; 59:574-580
5. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805-1812
6. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006; 27:902-907
7. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers, and non-smokers. Thorax 2006; 61:23-28
8. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the third National Health and Nutrition Examination. Am J Med 2003; 114:758-762
9. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med; 2006; 174:867-874
10. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760-765
11. Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep 2006; 8:421-428
12. Man SFP, Connett JE, Anthonisen NR, et al. C reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61:849-853
13. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in COPD. Am J Respir Crit Care Med 2007; 175:250-255
14. Celli BR, Cote CG, Marin JM, et al. The body mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005-1012
15. Casanova C, Cote C, de Torres JP, et al. The inspiratory to total lung capacity ratio predicts mortality in patients with COPD. Am J Respir Crit Care Med 2005; 171:591-577
16. Quanjer PH. Standardized lung function testing: report of the Working Party for the European Community for Steel and Coal. Bull Eur Physiopath Respir 1983; 19(suppl 5):22-27
17. Brooks SM. Surveillance for respiratory hazards. ATS News 1982; 8:12-16
18. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-117
19. Charlson M, Szatrowsky T, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-1251
20. Myers GL, Rifai N, Tracy RP, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. Circulation 2004; 110:e545-e549
21. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363-369
22. Linnemann B, Voigt W, Novel W, et al. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabet 2006; 114:127-134
23. Racki S, Zaputovic L, Mavric Z, et al. C-reactive protein is a strong predictor of mortality in hemodialysis patients. Ren Fail 2006; 427-433
24. Wilson PW, Nam BH, Pencina M, et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005; 165:2473-2478
25. Hansell A, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003; 22:809-814
26. Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic inflammation in COPD: is genetic susceptibility a key factor? COPD 2006; 3:51-61
27. Hersh CP, Miller DT, Kwiatkowski DJ, et al. Genetic determinants of C-reactive protein in COPD. Eur Respir J 2006; 28:1156-1162
28. Donaldson G. C-reactive protein: does it predict mortality? Am J Respir Crit Care Med 2006; 175:209-210
29. Jones PW, Agusti AGN. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27:822-832